Navigation Links
Clinical Trials for a Low-dose Steroid Therapy for Bone Marrow Cancer Prove Positive

Researchers see hopes in a new therapy combining low dose steroid with lenalidomide, already// found effective against multiple myeloma.

Multiple myeloma is a cancer of plasma cells that are found in blood and bone marrow.

Survival chances improved considerably when a low dose of the steroid dexamethasone combined with lenalidomide was tried on patients with newly diagnosed multiple myeloma.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The significance of the results lies in that a low dose regimen has been found to be more effective than the standard dose of dexamethasone.

Researchers found that patients in the study who received a lower dose regimen had a one-year survival of 96 percent compared to 86 per cent for patients treated in the case of those with the standard-dose of dexamethasone and lenalidomide.

In addition, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide.

"These results have major implications for myeloma therapy," noted study chair Vincent Rajkumar. "The results of this study, particularly lenalidomide plus low-dose dexamethasone, are very positive and in my opinion represent a real step forward in the treatment of this disease."

The application of this effective and less toxic approach is expected to benefit many patients with myeloma.

In 2007, an estimated 19,900 people in the United States will be diagnosed with multiple myeloma and an estimated 10,790 people will die of the disease.
SRM
'"/>




Page: 1

Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
8. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Cancer Clinical Research in India
11. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... ... Walk Away”: a captivating and romantic sequel to the romantic story of a ... creation of published author, Larry R. Sherman, a retired chemistry professor from the University ... well as four novels. , Though the book opens in 1947, when Edward ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... Although Labor ... of July, many communities have begun providing weekend displays, and numerous households celebrate the ... humans, they can be downright terrifying for pets. , Kris Zambo, owner of ...
(Date:8/21/2017)... ... 21, 2017 , ... Los Angeles area medical group Beverly ... year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, M.D. This one year ... Reconstructive Surgery. The candidate will have the opportunity to work with leading ...
(Date:8/21/2017)... ... 2017 , ... Marathon running has surged in popularity in ... running increases exposure to ultraviolet radiation, a carcinogen that promotes skin cancer. Studies ... half may be adequately protecting themselves with proper clothing and sunscreen. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
Breaking Medicine Technology: